Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  CareDx, Inc    CDNA

CAREDX, INC

(CDNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

CareDx's Patent Rights Upheld By Delaware Court

share with twitter share with LinkedIn share with facebook
share via e-mail
02/11/2020 | 07:01am EDT

SOUTH SAN FRANCISCO, Calif., Feb. 11, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that on February 10, 2020, Magistrate Judge Christopher Burke of the U.S. District Court for the District of Delaware recommended the denial of Natera Inc.’s and Eurofins Viracor, Inc.’s motions to dismiss CareDx’s patent infringement complaints against them.

CareDx alleges that both Natera’s and Viracor’s organ transplant products infringe CareDx’s patent rights. Natera and Viracor argued to the court that those patents are invalid because they allegedly cover ineligible subject matter. The court rejected their attack on the patents, explaining that the patents state that the invention is a “new, more accurate and useful analytic method” to help determine if a transplanted organ is rejected. The Court stated that the patents do not merely claim as the invention an unprotectable natural law.  

CareDx is very pleased with the court’s decision and is confident in the intellectual property rights protecting its industry leading organ transplant surveillance products. Edward Reines, counsel for CareDx, stated that “the Delaware court’s decision properly upholds CareDx’s patent rights with a well-reasoned legal analysis.” He further commented that “on the heels of CareDx’s success in its false advertising case against Natera, this courtroom success is another key step in its enforcement of its valid patent rights to protect its organ transplant surveillance products.”

About CareDx
CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients.

For more information, please visit: www.CareDx.com.

CONTACTS:
Greg Chodaczek
646-924-1769
investor@caredx.com

Primary Logo


© GlobeNewswire 2020
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on CAREDX, INC
03/20REPEAT - NEW AJT PUBLICATION : AlloSure Monitors First Patient Retransplanted Af..
GL
03/20NEW AJT PUBLICATION : AlloSure Monitors First Patient Retransplanted After Anti-..
GL
03/20NEW AJT PUBLICATION : AlloSure Monitors First Patient Retransplanted After Anti-..
AQ
03/17CAREDX LAUNCHES REMOTRAC : Home-Based Monitoring of Transplant Patients
GL
03/12CareDx Joins National Kidney Foundation on World Kidney Day to Support Kidney..
GL
03/05CareDx Brings Personalized Care to Transplant with the Launch of KIRA Immuno-..
GL
02/28CareDx to Participate in Upcoming Investor Conferences
GL
02/28CAREDX : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
AQ
02/27CAREDX : 4Q Earnings Snapshot
AQ
02/27CAREDX, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
More news
Financials (USD)
Sales 2020 167 M
EBIT 2020 -21,6 M
Net income 2020 -20,1 M
Debt 2020 -
Yield 2020 -
P/E ratio 2020 -48,9x
P/E ratio 2021 885x
Capi. / Sales2020 5,29x
Capi. / Sales2021 4,08x
Capitalization 885 M
Chart CAREDX, INC
Duration : Period :
CareDx, Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CAREDX, INC
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 45,00  $
Last Close Price 20,64  $
Spread / Highest target 186%
Spread / Average Target 118%
Spread / Lowest Target 69,6%
EPS Revisions
Managers
NameTitle
Peter K. Maag Chairman & Chief Executive Officer
Reginald Seeto President & Chief Business Officer
Paul Ciccolella Senior Vice President-Global Operations
Michael Bell Chief Financial & Principal Accounting Officer
Robert N. Woodward Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
CAREDX, INC-12.15%936
EXACT SCIENCES CORPORATION-39.72%8 582
GUARDANT HEALTH, INC.-22.59%6 569
IOVANCE BIOTHERAPEUTICS, INC.4.99%3 787
ADAPTIVE BIOTECHNOLOGIES CORPORATION-14.04%3 509
GENSCRIPT BIOTECH CORPORATION13.36%3 050